The cardiovascular benefit of GLP-1 receptor agonists is now established in the clinical literature, but the mechanism that produces it remains incompletely understood and is more interesting than the trial headlines suggest. GLP-1 receptor agonists a drug class that includes semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and tirzepatide (Mounjaro; dual GIP/GLP-1 receptor agonist) were originally developed to lower blood glucose through incretin-mediated insulin secretion. Their cardiovascular outcomes are not a pharmacological accident. They appear to arise from a combination of receptor-mediated and indirect metabolic mechanisms that operate simultaneously and, in some patients, synergistically.
This article examines the receptor biology, the downstream pathways that are plausibly responsible for cardiovascular benefit, and what the major cardiovascular outcomes trials LEADER, SUSTAIN-6, and SELECT have confirmed and left unresolved.
What the GLP-1 Receptor Does in Cardiac Tissue
Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by L-cells in the distal ileum and colon in response to nutrient ingestion. Its primary physiological role is to potentiate glucose-dependent insulin secretion from pancreatic beta cells the mechanism that was originally exploited in drug development. The GLP-1 receptor (GLP-1R) is a Class B G protein-coupled receptor that, on activation, couples primarily to adenylyl cyclase via the Gs alpha subunit, increasing intracellular cyclic AMP (cAMP) and activating protein kinase A (PKA) downstream.
GLP-1R is expressed not only in the pancreas and gut but in cardiac myocytes, vascular endothelial cells, smooth muscle cells, and macrophages. The cardiac expression of GLP-1R was identified before any of the major cardiovascular outcomes trials were conducted, and its presence in myocardial tissue raised the hypothesis subsequently supported by preclinical work that GLP-1 receptor agonism might exert direct cardioprotective effects beyond those attributable to weight loss, blood pressure reduction, or glycaemic improvement. Preclinical models demonstrated that GLP-1R activation in isolated cardiac myocytes reduced ischaemia-reperfusion injury, increased myocardial glucose uptake, and modulated calcium handling. These are preclinical findings and cannot be extrapolated directly to clinical outcomes; they provide mechanistic plausibility rather than proof of benefit.
The indirect pathways are mechanistically less elegant but clinically at least as important. GLP-1 receptor agonists reduce systolic blood pressure by 2 to 4 mmHg on average in clinical trials, an effect that is partially mediated by natriuresis and partially by reduced sympathetic tone. They lower body weight a central mechanism for cardiovascular risk reduction that operates through hypothalamic GLP-1R activation, reducing appetite and food intake via neural pathways rather than through peripheral metabolic effects alone. They reduce postprandial triglyceride excursions and reduce circulating concentrations of very-low-density lipoprotein particles. Each of these effects contributes independently to cardiovascular risk reduction and makes attributing the clinical outcomes trial results to any single mechanism unreliable.
What the Anti-Inflammatory Mechanism Adds
A third mechanistic layer that has attracted increasing attention is the anti-inflammatory activity of GLP-1R agonism. Atherosclerosis is fundamentally an inflammatory process, and macrophage-driven inflammation within the arterial wall is a proximate cause of plaque instability and acute cardiovascular events. GLP-1R is expressed on macrophages, and in vitro and animal data suggest that GLP-1R activation reduces macrophage activation, decreases release of pro-inflammatory cytokines including tumour necrosis factor-alpha and interleukin-6, and may reduce foam cell formation within atherosclerotic plaques. Whether this mechanism operates in human arterial disease at therapeutic drug concentrations remains an active research question. Evidence from the SELECT trial provides indirect support: semaglutide 2.4mg reduced high-sensitivity C-reactive protein (hsCRP) from baseline, suggesting a systemic anti-inflammatory effect independent of weight loss, though the trial was not designed to isolate this mechanism.
Real fact: GLP-1R is expressed in human coronary artery endothelial cells, smooth muscle cells, and macrophages, and its activation reduces foam cell formation and pro-inflammatory cytokine release in ex vivo models of atherosclerosis a mechanistic basis for direct vascular effects independent of metabolic improvements.
The endothelial effects of GLP-1R agonism include increased nitric oxide production, reduced expression of adhesion molecules that mediate leucocyte trafficking into the arterial wall, and reduced endothelial oxidative stress. These effects are measurable in human endothelial cell models and have been observed in some clinical biomarker studies, but translating endothelial biology to clinical event reduction requires caution. The SELECT trial remains the most powerful evidence that cardiovascular benefit extends beyond glycaemic management.
What the Major Trials Confirmed
The LEADER trial (Marso et al., New England Journal of Medicine, 2016) was the first cardiovascular outcomes trial in the GLP-1 receptor agonist class to demonstrate a statistically significant reduction in major adverse cardiovascular events (MACE). The trial enrolled 9,340 patients with type 2 diabetes and high cardiovascular risk, randomised them to liraglutide 1.8mg daily or placebo, and followed them for a median of 3.8 years. The primary composite endpoint cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke occurred in 13.0% of liraglutide-treated patients versus 14.9% in the placebo group (HR 0.87; 95% CI: 0.78 to 0.97; p = 0.01 for superiority). The number needed to treat to prevent one MACE event over the trial duration was approximately 66. The reduction was driven primarily by cardiovascular mortality rather than non-fatal MI or stroke a finding that is mechanistically suggestive of an effect on myocardial ischaemia or sudden cardiac death rather than plaque rupture events alone. The trial was sponsored by Novo Nordisk; no relevant conflicts of interest were reported that would materially affect the primary endpoint interpretation.
The SUSTAIN-6 trial (Marso et al., New England Journal of Medicine, 2016) evaluated semaglutide 0.5mg and 1.0mg subcutaneous weekly in 3,297 patients with type 2 diabetes at high cardiovascular risk. At a median follow-up of 2.1 years, MACE occurred in 6.6% of semaglutide-treated patients versus 8.9% of placebo patients (HR 0.74; 95% CI: 0.58 to 0.95; p < 0.001 for non-inferiority; p = 0.02 for superiority). The reduction in stroke was particularly notable, a finding that has since influenced NICE guidance on semaglutide's use in high-risk cardiovascular populations. SUSTAIN-6 was a cardiovascular safety trial rather than a trial powered for superiority; the non-fatal stroke finding requires confirmation in a larger dedicated dataset. The trial was sponsored by Novo Nordisk.
The SELECT trial (Lincoff et al., New England Journal of Medicine, 2023) is the most clinically significant cardiovascular outcomes trial in the class to date, because it enrolled patients without diabetes, a population where the cardiovascular effect cannot be attributed to glycaemic improvement at all. The trial randomised 17,604 adults with established cardiovascular disease and a body mass index of 27 or higher to semaglutide 2.4mg weekly (the obesity-licensed dose, marketed as Wegovy) or placebo. At a mean follow-up of 39.8 months, MACE occurred in 6.5% of semaglutide-treated patients versus 8.0% of placebo patients (HR 0.80; 95% CI: 0.72 to 0.90; p < 0.001). The absolute risk reduction of 1.5 percentage points translates to a number needed to treat of approximately 67 over the trial duration. The effect on MACE was consistent across prespecified subgroups including sex, age, BMI, and prior MI. The trial was sponsored by Novo Nordisk; multiple authors declared relationships with pharmaceutical companies including Novo Nordisk, which is customary in outcomes trials of this scale and does not alone invalidate the findings.
The SELECT trial cannot, from its design, isolate which mechanism is responsible for the cardiovascular benefit. Weight loss, blood pressure reduction, anti-inflammatory effects, and direct cardiac effects all occurred concurrently. A mediation analysis published as a secondary analysis suggested that less than 50% of the cardiovascular benefit was mediated by weight loss pointing to mechanisms operating independently of body weight but mediation analyses carry methodological limitations and should be interpreted as hypothesis-generating rather than definitive.
What the UK Prescribing Position Looks Like
In the United Kingdom, MHRA-licensed indications for GLP-1 receptor agonists span type 2 diabetes management (liraglutide, semaglutide subcutaneous, dulaglutide, exenatide) and weight management (semaglutide 2.4mg, liraglutide 3mg). NICE technology appraisal TA875 (semaglutide 2.4mg for weight management, 2023) provides access for patients with a BMI of 35 or higher and at least one weight-related comorbidity through specialist weight management services on the NHS. The cardiovascular indication from SELECT data was factored into a subsequent NICE review, and as of early 2025 NICE recommends semaglutide 2.4mg in patients with established cardiovascular disease and obesity as a component of cardiovascular risk reduction, marking the first time a GLP-1 receptor agonist has been recommended by NICE for a non-glycaemic cardiovascular indication.
Tirzepatide (Mounjaro) received MHRA authorisation for type 2 diabetes in 2023 and for weight management in 2024. As a dual GIP/GLP-1 receptor agonist, tirzepatide's cardiovascular mechanism includes GIP receptor-mediated effects in addition to GLP-1R agonism; the SURMOUNT-MMO cardiovascular outcomes trial is ongoing and its results are awaited before the cardiovascular position for tirzepatide can be established with the same confidence as semaglutide.
Outstanding Questions
The cardiovascular outcomes benefit of GLP-1 receptor agonists is established for semaglutide in both diabetic and non-diabetic populations. What remains unresolved is the precise mechanistic hierarchy. Whether the direct cardiac and vascular receptor-mediated effects, the anti-inflammatory pathway, the metabolic improvements, or the weight loss component contributes most to the observed MACE reduction cannot be determined from the available clinical trial data. This matter because it determines which patients are most likely to benefit, at what dose, and for how long.
Heart rate increase is a consistent pharmacodynamic effect of GLP-1R agonism semaglutide increases resting heart rate by 1 to 4 beats per minute whose long-term significance is not established. In the cardiovascular outcomes trials this effect did not attenuate benefit, but its mechanism (sympathetic activation vs direct sinoatrial node GLP-1R effect) and its relevance in patients with pre-existing arrhythmia requires further characterisation.
The cardiovascular trials to date have enrolled predominantly patients with established disease and high risk. Extrapolating the results to primary prevention populations, younger patients, or patients with BMI below 27 is not supported by current evidence and should not be done in clinical practice without acknowledgement that the data do not apply.
The mechanistic evidence for GLP-1 receptor agonists suggests a drug class that arrived as a glucose-lowering agent and turned out to be something more complex not unlike penicillin's relationship to the original mould. The cardiovascular story is still being written, and the next chapter will determine whether the benefit belongs to the receptor, the weight loss, or the combination.
Related reading
PCSK9 Inhibitors and LDL Reduction Beyond the Statin Ceiling
Semaglutide Trial Data in Early Alzheimer Disease Shows a Signal
